Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease

NCT05797597 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

76

Enrollment

OTHER

Sponsor class

Conditions

AERD - Aspirin Exacerbated Respiratory Disease

Interventions

DRUG: Aspirin 300 Mg Oral Tablet
DRUG: Placebo

Sponsor

Lucyna Mastalerz